MicroPET imaging of integrin α vβ 3 expressing tumors using 89Zr-RGD peptides

Molecular Imaging and Biology

Volumn 13, Issue 6, 2011, Pages 1224-1233

  Jacobson, Orit ^a   Zhu, Lei ^a,b   Niu, Gang ^a   Weiss, Ido D ^c   Szajek, Lawrence P ^d   Ma, Ying ^a   Sun, Xilin ^a   Yan, Yongjun ^a   Kiesewetter, Dale O ^a   Liu, Shuang ^e   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b JILIN UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

89Zr zirconium; Integrin v 3; PET; RGD peptides

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ZIRCONIUM; ZIRCONIUM 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COMPLEX FORMATION; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY;

ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; HUMANS; INTEGRIN ALPHAVBETA3; IODINE RADIOISOTOPES; LIGANDS; MICE; MICE, NUDE; NEOPLASMS; OLIGOPEPTIDES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION; ZIRCONIUM;

ANIMALIA;

EID: 84855651759     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0458-y     Document Type: Article

References (45)

1. Liu S (2009) Radiolabeled cyclic RGD peptides as integrin avß3- targeted radiotracers: Maximizing binding affinity via bivalency. Bioconjug Chem 20:2199-2213
2. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
3. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395 (Pubitemid 30208155)
4. Sengupta S, Chattopadhyay N, Mitra A, Ray S, Dasgupta S, Chatterjee A (2001) Role of avß3 integrin receptors in breast tumor. J Exp Clin Cancer Res 20:585-590 (Pubitemid 34087493)
5. Wang L, Shi J, Kim YS, Zhai S, Jia B, Zhao H et al (2009) Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm 6:231-245
6. Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M et al (2004) MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 31:1081-1089 (Pubitemid 39050174)
7. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR et al (2004) MicroPET imaging of breast cancer av-integrin expression with 64Culabeled dimeric RGD peptides. Mol Imaging Biol 6:350-359 (Pubitemid 39243068)
8. Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS (2004) Micro- PET imaging of avß3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3:96-104
9. Dijkgraaf I, Beer AJ, Wester HJ (2009) Application of RGD-containing peptides as imaging probes for avß3 expression. Front Biosci 14:887-899
10. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC et al (2001) avß3 and avß5 integrin expression in glioma periphery. Neurosurgery 49:380-389, discussion 90
11. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA (1992) Involvement of integrin av gene expression in human melanoma tumorigenicity. J Clin Invest 89:2018-2022
12. Robinson SD, Reynolds LE, Wyder L, Hicklin DJ, Hodivala-Dilke KM (2004) ß3-integrin regulates vascular endothelial growth factor-Adependent permeability. Arterioscler Thromb Vasc Biol 24:2108-2114 (Pubitemid 39482438)
13. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS et al (2006) Quantitative PET imaging of tumor integrin avß3 expression with 18FFRGD2. J Nucl Med 47:113-121
14. Chen X (2006) Multimodality imaging of tumor integrin avß3 expression. Mini Rev Med Chem 6:227-234
15. Cai W, Niu G, Chen X (2008) Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 14:2943-2973
16. Liu S (2006) Radiolabeled multimeric cyclic RGD peptides as integrin avß3 targeted radiotracers for tumor imaging. Mol Pharm 3:472-487 (Pubitemid 44639125)
17. Bogler O, Mikkelsen T (2003) Angiogenesis in glioma: Molecular mechanisms and roadblocks to translation. Cancer J 9:205-213
18. Hwang R, Varner J (2004) The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 18:991-1006, vii
19. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G et al (1994) Integrin avß3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164
20. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin avß3 for angiogenesis. Science 264:569-571
21. Dayton PA, Pearson D, Clark J, Simon S, Schumann PA, Zutshi R et al (2004) Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of avß3-expressing cells. Mol Imaging 3:125-134
22. Ellegala DB, Leong-Poi H, Carpenter JE, Klibanov AL, Kaul S, Shaffrey ME et al (2003) Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to avß3. Circulation 108:336-341 (Pubitemid 36899026)
23. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR (2003) Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to av-integrins. Circulation 107:455-460 (Pubitemid 36158049)
24. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC (1998) Detection of tumor angiogenesis in vivo by avß3-targeted magnetic resonance imaging. Nat Med 4:623-626 (Pubitemid 28237365)
25. Chen X, Conti PS, Moats RA (2004) In vivo near-infrared fluorescence imaging of integrin avß3 in brain tumor xenografts. Cancer Res 64:8009-8014 (Pubitemid 39446936)
26. Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH et al (2004) 18F-labeled RGD peptide: Initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 31:179-189 (Pubitemid 38315112)
27. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS (2004) MicroPET and autoradiographic imaging of breast cancer av-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 15:41-49 (Pubitemid 38165979)
28. Chen X, Park R, Shahinian AH, Bading JR, Conti PS (2004) Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31:11-19 (Pubitemid 38115121)
29. Chen X, Hou Y, Tohme M, Park R,Khankaldyyan V, Gonzales-Gomez I et al (2004) Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor avß3-integrin expression. J Nucl Med 45:1776-1783 (Pubitemid 47618490)
30. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL et al (2001) Noninvasive imaging of avß3 integrin expression using 18Flabeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785 (Pubitemid 32691983)
31. Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M, Wester HJ (2004) Synthesis and biological evaluation of a 99mTclabelled cyclic RGD peptide for imaging the avß3 expression. Nuklearmedizin 43:26-32 (Pubitemid 38233141)
32. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ et al (2004) [18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15:61-69 (Pubitemid 38165981)
33. Li ZB, Chen K, Chen X (2008) 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin avß3 expression. Eur J Nucl Med Mol Imaging 35:1100-1108
34. Wu Z, Li ZB, Chen K, Cai W, He L, Chin FT et al (2007) microPET of tumor integrin avß3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 48:1536-1544 (Pubitemid 47397404)
35. Holland JP, Sheh Y, Lewis JS (2009) Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36:729-739
36. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE et al (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate pisothiocyanatobenzyl- desferrioxamine. Nat Protoc 5:739-743
37. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S et al (2005) microPET imaging of glioma integrin avß3 expression using 64Culabeled tetrameric RGD peptide. J Nucl Med 46:1707-1718 (Pubitemid 46211595)
38. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS et al (2002) Comparison of a monomeric and dimeric radiolabeled RGDpeptide for tumor targeting. Cancer Biother Radiopharm 17:641-646 (Pubitemid 36025945)
39. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H et al (1999) Radiolabeled avß3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 40:1061-1071 (Pubitemid 29269229)
40. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586-592
41. Tinianow JN, Gill HS, Ogasawara A, Flores JE, Vanderbilt AN, Luis E et al (2010) Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol 37:289-297
42. Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E et al (2010) PET of hypoxia with 89Zr-labeled cG250-F(ab ')2 in head and neck tumors. J Nucl Med 51:1076-1083
43. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51:1293-1300
44. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S (2009) Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem 20:750-759
45. Meijs WE, Herscheid JDM, Haisma H, Pinedo HM (1992) Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Appl Radiat Isot 43:1443-1447